News

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results

April 02, 2018

REDWOOD CITY, Calif. , April 02, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage ...

Read More

Soleno Therapeutics Announces Successful End-of-Phase II Meeting with FDA for DCCR in Prader-Willi Syndrome

February 20, 2018

Minutes Confirm Alignment on Soleno’s Planned Phase III Clinical Trial Soleno In Process of ...

Read More

Soleno Therapeutics Announces $15 Million Private Placement

December 12, 2017

Financing to Support Planned Phase III Clinical Program for DCCR in Prader-Willi Syndrome REDWOOD CITY, ...

Read More
Soleno – Home